A US Cambridge, Massachusetts based Moderna just released a media press with which to announce the primary efficacy analysis in the Phase 3 COVE study for mRNA-1273, their covid-19 vaccine, they plan to request an emergency use authorisation from the United States and Europe.
In April, Moderna announced that they received an award from US Government Agency BARDA for up to $483 million to accelerate the development of mRNA vaccine against novel coronavirus.
The firm full results confirmed a high efficacy estimated at 94.1 percentile. In the press release where the aspiration to make such a request was announced, the frim said, “we believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic and help prevent severe disease, hospitalisations and death.”
The world awaited the vaccine until hope was lost, I wish it’s safe to say eventually the vaccine’s found and lives would be saved, albeit that merely lies in the hand of the US Food and Drug Administration as they might find or not find the drug safe and effective. The world, of course, wishes for the safety and effectiveness thereof.
If it is find effectively safe to utilise, eNCA sees the first of the drug’s two doses injected into the arms of of millions of Americans by the middle of December.
Good news is the world sees the use and need of Moderna’s vaccines as UK has bought 7 million doses of the vaccine, initial GB bought 5 million shortly after the announcement of the drug efficacy, and the last 2 million last week. despite the purchase made, the supplies of the vaccine to the UK are not anticipated until March 2021.
The Guardian reported that even though the firm has done deals from international borders, the US will get access first as it has put $2.48 billion in the firm and was a key part of the Trump administration’s Operation Warp Speed. Moderna said it anticipated to have about 20 million doses available for the US prior the end of this year.